Production of profibrotic cytokines by invariant NKT cells characterizes cirrhosis progression in chronic viral hepatitis

Journal of Immunology

Volumn 173, Issue 2, 2004, Pages 1417-1425

  De Lalla, Claudia ^a   Galli, Grazia ^c   Aldrighetti, Luca ^b   Romeo, Raffaella ^d   Mariani, Margherita ^e   Monno, Antonella ^a   Nuti, Sandra ^c   Colombo, Massimo ^d   Callea, Francesco ^f   Porcelli, Steven A ^g   Panina Bordignon, Paola ^e   Abrignani, Sergio ^c   Casorati, Giulia ^a,b   Dellabona, Paolo ^a,b  

^a Cellular Immunology Unit   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c CHIRON VACCINES   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e BioXell SpA   (Italy)

^f BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^g ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD1D ANTIGEN; CYTOKINE; INTERLEUKIN 13; INTERLEUKIN 4; LIGAND; LIPID;

ADULT; AGED; ANTIGEN PRESENTING CELL; ARTICLE; CELL ACTIVATION; CHRONIC HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; INVARIANT NKT CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER INJURY; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; STRESS; T LYMPHOCYTE SUBPOPULATION; TISSUE INJURY;

EID: 3142687525     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.173.2.1417     Document Type: Article

References (46)

1. Lee, W. M. 1997. Hepatitis B virus infection. N. Engl. J. Med. 337:1733.
2. Liang, T. J., B. Rehermann, L. B. Seeff, and J. H. Hoofnagle. 2000. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann. Intern. Med. 132:296.
3. Friedman, S. L. 2000. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J. Biol. Chem. 275:2247.
4. Seeff, L. B. 2002. Natural history of chronic hepatitis C. Hepatology 36:S35.
5. Marcellin, P., T. Asselah, and N. Boyer. 2002. Fibrosis and disease progression in hepatitis C. Hepatology 36:S47.
6. Romeo, R., and M. Colombo. 2002. The natural history of hepatocellular carcinoma. Toxicology 181:39.
7. Wynn, T. A. 2003. IL-13 effector functions. Annu. Rev. Immunol. 21:425.
8. Kodera, T., T. L. McGaha, R. Phelps, W. E. Paul, and C. A. Bona. 2002. Disrupting the IL-4 gene rescues mice homozygous for the tight-skin mutation from embryonic death and diminishes TGF-β production by fibroblasts. Proc. Natl. Acad. Sci. USA 99:3800.
9. Bendelac, A., M. N. Rivera, S. H. Park, and J. H. Roark. 1997. Mouse CD1-specific NK1 T cells: development, specificity, and function. Annu. Rev. Immunol. 15:535.
10. -8- T cells. J. Exp. Med. 180:1171.
11. -8- T cells in mice and humans. J. Exp. Med. 180:1097.
12. + T lymphocytes. Science 268:863.
13. Kawano, T., J. Cui, Y. Koezuka, I. Toura, Y. Kaneko, K. Motoki, H. Ueno, R. Nakagawa, H. Sato, E. Kondo, et al. 1997. CD1d-restricted and TCR-mediated activation of Vα14 NKT cells by glycosylceramides. Science 278:1626.
14. -CD8- T cells. J. Exp. Med. 186:109.
15. Gumperz, J. E., and M. B. Brenner. 2001. CD1-specific T cells in microbial immunity. Curr. Opin. Immunol. 13:471.
16. Smyth, M. J., N. Y. Crowe, Y. Hayakawa, K. Takeda, H. Yagita, and D. I. Godfrey. 2002. NKT cells: conductors of tumor immunity? Curr. Opin. Immunol. 14:165.
17. Wilson, M. T., A. K. Singh, and L. Van Kaer. 2002. Immunotherapy with ligands of natural killer T cells. Trends Mol. Med. 8:225.
18. Kaneko, B. Y., M. Harada, T. Kawano, M. Yamashita, Y. Shibata, F. Gejyo, T. Nakayama, and M. Taniguchi. 2000. Augmentation of Vα14 NKT cell-mediated cytotoxicity by interleukin 4 in an autocrine mechanism resulting in the development of concanavalin A-induced hepatitis. J. Exp. Med. 191:105.
19. Naka, T., H. Tsutsui, M. Fujimoto, Y. Kawazoe, H. Kohzaki, Y. Morita, R. Nakagawa, M. Narazaki, K. Adachi, T. Yoshimoto, et al. 2001. SOCS-1/SSI-1-deficient NKT cells participate in severe hepatitis through dysregulated cross-talk inhibition of IFN-γ and IL-4 signaling in vivo. Immunity 14:535.
20. Ishak, K., A. Baptista, L. Bianchi, F. Callea, J. De Groote, F. Gudat, H. Denk, V. Desmet, G. Korb, R. N. MacSween, et al. 1995. Histological grading and staging of chronic hepatitis. J. Hepatol. 22:696.
21. Galli, G., S. Nuti, S. Tavarini, L. Galli-Stampino, C. De Lalla, G. Casorati, P. Dellabona, and S. Abrignani. 2003. CD1d-restricted help to B cells by human invariant natural killer T lymphocytes. J. Exp. Med. 197:1051.
22. Exley, M., J. Garcia, S. B. Wilson, F. Spada, D. Gerdes, S. M. Tahir, K. T. Patton, R. S. Blumberg, S. Porcelli, A. Chott, and S. P. Balk. 2000. CD1d structure and regulation on human thymocytes, peripheral blood T cells, B cells and monocytes. Immunology 100:37.
23. Karadimitris, A., S. Gadola, M. Altamirano, D. Brown, A. Woolfson, P. Klenerman, J. L. Chen, Y. Koezuka, I. A. Roberts, D. A. Price, et al. 2001. Human CD1d-glycolipid tetramers generated by in vitro oxidative refolding chromatography. Proc. Natl. Acad. Sci. USA 98:3294.
24. Kenna, T., L. G. Mason, S. A. Porcelli, Y. Koezuka, J. E. Hegarty, C. O'Farrelly, and D. G. Doherty. 2003. NKT cells from normal and tumor-bearing human livers are phenotypically and functionally distinct from murine NKT cells. J. Immunol. 171:1775.
25. + T cells with type 1 or type 2 cytokine profile are related to different disease activity in chronic hepatitis C virus infection. Eur. J. Immunol. 31:894.
26. + T-cell and cytokine response. Gastroenterology 121:646.
27. Knodell, R. G., K. G. Ishak, W. C. Black, T. S. Chen, R. Craig, N. Kaplowitz, T. W. Kiernan, and J. Wollman. 1981. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1:431.
28. Bleicher, P. A., S. P. Balk, S. J. Hagen, R. S. Blumberg, T. J. Flotte, and C. Terhorst. 1990. Expression of murine CD1 on gastrointestinal epithelium. Science 250:679.
29. Brossay, L., D. Jullien, S. Cardell, B. C. Sydora, N. Burdin, R. L. Modlin, and M. Kronenberg. 1997. Mouse CD1 is mainly expressed on hemopoietic-derived cells. J. Immunol. 159:1216.
30. Nuti, S., D. Rosa, N. M. Valiante, G. Saletti, M. Caratozzolo, P. Dellabona, V. Barnaba, and S. Abrignani. 1998. Dynamics of intra-hepatic lymphocytes in chronic hepatitis C: enrichment for Vα24/Vβ11 T cells and rapid elimination of effector cells by apoptosis. Eur. J. Immunol. 28:3448.
31. Lucas, M., S. Gadola, U. Meier, N. T. Young, G. Harcourt, A. Karadimitris, N. Coumi, D. Brown, G. Dusheiko, V. Cerundolo, and P. Klenerman. 2003. Frequency and phenotype of circulating Vα24/Vβ11 double-positive natural killer T cells during hepatitis C virus infection. J. Virol. 77:2251.
32. Kita, H., O. V. Naidenko, M. Kronenberg, A. A. Ansari, P. Rogers, X. S. He, F. Koning, T. Mikayama, J. Van De Water, R. L. Coppel, et al. 2002. Quantitation and phenotypic analysis of natural killer T cells in primary biliary cirrhosis using a human CD1d tetramer. Gastroenterology 123:1031.
33. Mempel, M., C. Ronet, F. Suarez, M. Gilleron, G. Puzo, L. Van Kaer, A. Lehuen, P. Kourilsky, and G. Gachelin. 2002. Natural killer T cells restricted by the monomorphic MHC class 1b CD1d1 molecules behave like inflammatory cells. J. Immunol. 168:365.
34. Kim, C. H., E. C. Butcher, and B. Johnston. 2002. Distinct subsets of human Vα24-invariant NKT cells: cytokine responses and chemokine receptor expression. Trends Immunol. 23:516.
35. Bendelac, A., M. Bonneville, and J. F. Kearney. 2001. Autoreactivity by design: innate B and T lymphocytes. Nat. Rev. Immunol. 1:177.
36. Kitamura, H., K. Iwakabe, T. Yahata, S. Nishimura, A. Ohta, Y. Ohmi, M. Sato, K. Takeda, K. Okumura, L. Van Kaer, et al. 1999. The natural killer T (NKT) cell ligand α-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J. Exp. Med. 189:1121.
37. Ikarashi, Y., R. Mikami, A. Bendelac, M. Terme, N. Chaput, M. Terada, T. Tursz, E. Angevin, F. A. Lemonnier, H. Wakasugi, and L. Zitvogel. 2001. Dendritic cell maturation overrules H-2D-mediated natural killer T (NKT) cell inhibition: critical role for B7 in CD1d-dependent NKT cell interferon γ production. J. Exp. Med. 194:1179.
38. Vincent, M. S., D. S. Leslie, J. E. Gumperz, X. Xiong, E. P. Grant, and M. B. Brenner. 2002. CD1-dependent dendritic cell instruction. Nat. Immunol. 3:1163.
39. Leite-De-Moraes, M. C., A. Hameg, M. Pacilio, Y. Koezuka, M. Taniguchi, L. Van Kaer, E. Schneider, M. Dy, and A. Herbelin. 2001. IL-18 enhances IL-4 production by ligand-activated NKT lymphocytes: a pro-Th2 effect of IL-18 exerted through NKT cells. J. Immunol. 166:945.
40. McGuinness, P. H., D. Painter, S. Davies, and G. W. McCaughan. 2000. Increases in intrahepatic CD68 positive cells, MAC387 positive cells, and proinflammatory cytokines (particularly interleukin 18) in chronic hepatitis C infection. Gut 46:260.
41. Lee, P. T., K. Benlagha, L. Teyton, and A. Bendelac. 2002. Distinct functional lineages of human Vα24 natural killer T cells. J. Exp. Med. 195:637.
42. Gumperz, J. E., S. Miyake, T. Yamamura, and M. B. Brenner. 2002. Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J. Exp. Med. 195:625.
43. Tahir, S. M., O. Cheng, A. Shaulov, Y. Koezuka, G. J. Bubley, S. B. Wilson, S. P. Balk, and M. A. Exley. 2001. Loss of IFN-γ production by invariant NK T cells in advanced cancer. J. Immunol. 167:4046.
44. Dhodapkar, M. V., M. D. Geller, D. H. Chang, K. Shimizu, S. Fujii, K. M. Dhodapkar, and J. Krasovsky. 2003. A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. J. Exp. Med. 197:1667.
45. Postlethwaite, A. E., M. A. Holness, H. Katai, and R. Raghow. 1992. Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4. J. Clin. Invest. 90:1479.
46. Terabe, M., S. Matsui, J. M. Park, M. Mamura, N. Noben-Trauth, D. D. Donaldson, W. Chen, S. M. Wahl, S. Ledbetter, B. Pratt, et al. 2003. Transforming growth factor-β production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J. Exp. Med. 198:1741.